Development and Characterization of Ungual Drug Delivery System

Shweta Ashok Dandawate
Kasturi Shikshan Sanstha Pharmacy Collage Shikrapur

Abstract- Ungual drug delivery, commonly referred to as transungual delivery, represents an emerging and specialized therapeutic approach for treating various nail disorders through localized administration of pharmaceuticals directly to the nail plate. The nail plate, composed of densely keratinized structures with exceptional structural integrity, presents unique and complex challenges alongside distinctive opportunities for pharmaceutical delivery. This comprehensive review systematically examines the development, characterization, and clinical application of ungual drug delivery systems (UDDS), with particular emphasis on mechanisms facilitating drug penetration through the nail barrier, diverse permeation enhancement strategies, and expanding therapeutic applications[1]. Nail disorders affect millions globally, with fungal infections (onychomycosis) affecting approximately 10-12% of the population, and current systemic treatments frequently result in adverse effects and suboptimal efficacy. Ungual delivery systems overcome inherent anatomical barriers through multiple complementary mechanisms including chemical permeation enhancement using polyethylene glycols and cyclodextrins, physical enhancement through iontophoresis and sonophoresis, and advanced nanotechnology platforms incorporating liposomes and polymeric micelles[2]. Applications extend substantially beyond fungal infections to include nail psoriasis, paronychia, and yellow nail syndrome, representing significant clinical advancement over conventional topical and systemic therapies. This comprehensive review synthesizes current understanding of ungual delivery mechanisms, permeation enhancement approaches, clinical applications, and future perspectives to provide a comprehensive foundation for continued advancement in this specialized pharmaceutical field.

Keywords: Ungual delivery, Transungual delivery, Nail drug delivery, Onychomycosis, Permeation enhancement, Nail barrier, Nanoliposomes, Drug penetration, Keratinized tissue, Pharmaceutical formulation

I.INTRODUCTION

For thousands of years, nails have been recognized as important anatomical structures, yet their therapeutic potential remained largely unexploited until recent decades. The nail plate, an appendage composed of highly organized keratinized cells, presents both exceptional challenges and distinctive opportunities for pharmaceutical intervention. Ungual drug delivery, derived from the Latin term "unguis" meaning nail, refers specifically to the therapeutic administration of pharmaceutical agents through the nail plate to achieve localized or systemic therapeutic effects[3]. This specialized route of drug administration represents a unique intersection between dermatological therapy and advanced pharmaceutical technology, opening new possibilities for treating conditions previously considered difficult to manage.

Transungual drug delivery specifically denotes the transport of drugs across the nail plate to reach the underlying nail bed and diseased tissues, thereby circumventing traditional systemic absorption pathways. Unlike conventional topical applications to skin, ungual delivery systems create a distinctive depot effect on the nail surface, enabling sustained and continuous drug release over extended periods. This characteristic allows for significantly reduced application frequencies compared to traditional treatment modalities, representing a substantial improvement in patient compliance and quality of life[4]. The nail plate barrier, while presenting exceptional challenges to drug penetration due to its remarkable structural organization, offers unique advantages for localized therapeutic delivery that warrant systematic scientific investigation.

Historical Development and Clinical Evolution

The concept of nail drug delivery emerged during the 1980s when researchers recognized the clinical limitations of conventional topical treatments for persistent nail disorders. Early investigations focused on understanding nail physiology and identifying specific barriers to drug penetration. The first marketed ungual delivery product was amorolfine nail lacquer, approved in Europe during the 1990s, which revolutionized the treatment approach for onychomycosis by achieving superior efficacy compared to earlier topical agents[5]. Subsequently, ciclopirox nail lacquer became the first FDA-approved topical antifungal specifically for nail infections in the United States, establishing regulatory recognition of this specialized delivery route.

These pioneering products established the scientific foundation for systematic exploration of ungual delivery mechanisms, leading to progressive refinement of delivery technologies and expansion of therapeutic applications. Over the past two decades, research has intensified regarding fundamental mechanisms of drug penetration through keratinized tissue, optimal formulation strategies for enhancing drug delivery, and clinical translation of laboratory discoveries into therapeutic products[6].

Clinical Significance and Therapeutic Need

Nail disorders represent a significant global health burden affecting quality of life, work productivity, and psychological well-being to an often underestimated degree. Onychomycosis, the most prevalent nail disorder, accounts for approximately 50% of all nail pathology and affects 10-12% of the general population globally[7]. The prevalence increases substantially in elderly populations (20-25%) and immunocompromised individuals, making it a major public health concern. Current systemic treatments using oral antifungals such as terbinafine and itraconazole, while possessing inherent efficacy, carry substantial risks of hepatotoxicity, drug-drug interactions, and cardiovascular complications, limiting their use in patients with comorbidities or polypharmacy[8].

Topical delivery through the nail route circumvents first-pass hepatic metabolism and systemic absorption, reducing adverse effects while maintaining high local concentrations at the disease site. This approach proves particularly valuable for elderly patients and those with compromised liver function. Beyond fungal infections, nail psoriasis affects 10-55% of patients with systemic psoriasis, and ungual delivery offers targeted treatment options with reduced systemic exposure. Other nail conditions including paronychia, yellow nail syndrome, and lichen planus affecting the nail unit have emerged as potential indications for specialized ungual delivery systems.

Types of Ungual Drug Delivery Systems

Nail Lacquers

Nail lacquers (or “paints”) are polymer-based solutions that dry to form a thin film on the nail surface. Typically containing film-forming (water-soluble or insoluble) polymers and volatile solvents, they rapidly solidify into a smooth, occlusive layer that serves as a drug depot on the nail plate. Clinically (e.g. amorolfine, ciclopirox lacquers) this approach has dramatically improved onychomycosis therapy: lacquer-based regimens have achieved mycological cure rates on the order of 60–70% at 12 months while avoiding systemic toxicity. Advantages include prolonged local drug exposure and ease of application, permitting high local concentrations with minimal systemic absorption. Key limitations are the inherently slow permeation through dense keratin – necessitating treatment courses of many months – and potential loss of the film by washing or abrasion.

- Formulation: Film-forming polymer + volatile solvent → dries to uniform film on nail.
- Advantages: Sustained release from the polymeric film allows high local drug levels (e.g. 60–70% cure in chronic onychomycosis) with negligible systemic exposure. Improved patient adherence is achieved via reduced dosing frequency and a cosmetic, depot-like effect on the nail.
- Limitations: Nail-plate permeability remains a challenge. Drug must diffuse through tightly cross-linked keratin, so complete treatment often requires 6–12 months. The lacquer film can flake or be removed by washing, and variation in nail thickness affects dosing.

Films and Patches

Pressure-sensitive films or patches are thin polymeric layers adhering to the nail by a tacky adhesive backing. A typical design combines a drug reservoir (polymeric adhesive matrix) with an impermeable backing and release liner. Once applied to the nail, the patch continuously delivers drug across the nail plate over time. Because they provide a controlled "matrix" delivery, patches often yield more sustained release than simple lacquers, enhancing efficacy and patient compliance.

- Mechanism: Polymeric film adhered to nail (backed by laminate) that gradually releases drug from the adhesive reservoir.
- Advantages: Continuous, controlled release maintains therapeutic levels at the nail bed. Reduced dosing frequency improves compliance compared to creams. The backing protects the drug layer from immediate loss by water or abrasion.
- Limitations: Patches may cause local irritation or allergic reaction to adhesives. They must be cut to fit nail shape, which complicates use. Adhesive failure or lifting can interrupt therapy, and drug loading is limited by patch size/thickness.

Gels and Creams

Gels (often hydrogels) and semi-solid creams are viscous matrices designed to contact the nail plate. Hydrogels consist of hydrophilic polymer networks that can retain large amounts of water. By hydrating the nail, these systems improve drug diffusion: the absorbed water swells keratin and opens aqueous channels in the nail plate. Creams (oil-in-water or water-in-oil emulsions) similarly provide a drug-carrier medium, though most formulations for nails emphasize gels.

- Formulation: Hydrophilic polymer gel or emulsion applied to the nail surface. The gel's 3D network holds the drug and water, promoting penetration.
- Advantages: High water content hydrates and plasticizes the nail, facilitating drug uptake. Gels can be more comfortable and spreadable than films, and can incorporate chemical penetration enhancers. In situ gelling systems (liquid on application that solidify) improve retention.
- Limitations: Gels can be runny or dilute (risking wash-off) and may require additives or occlusion to stay in place. High viscosity (and stickiness) can reduce patient comfort. Many gels/creams require daily reapplication because they are readily removed by water or rubbing, leading to limited depot effect.

Nanocarrier–Based Systems

Nanoscale carriers (liposomes, nanoemulsions, polymeric nanoparticles, solid lipid nanoparticles, etc.) have been adapted for nail delivery. These systems encapsulate the drug in a sub-micron vehicle: for example, lipid vesicles or polymeric nanospheres. Their small size (typically 10–200 nm) allows closer interaction with the nail plate and more effective permeation through micro-pores or keratin gaps. In addition, nanocarriers can be engineered for controlled/sustained release and protection of labile drugs.

- Platform: Lipid or polymeric nanoparticles, nanoemulsions, micelles, etc., formulated to carry antifungal or other agents through the nail. (E.g. liposomes or solid lipid NPs are two common examples.)
- Advantages: Enhanced penetration and deposition in the nail due to small particle size. Can solubilize poorly soluble drugs, provide sustained release, and target drug release (prolonging effect). Some carriers fuse with keratin or form concentration gradients that drive drug into the nail.
- Limitations: Complex manufacturing and stability issues. Formulations often require surfactants or co-solvents that may irritate. Potential toxicity of nano-carrier materials (e.g. preservatives or metal cores) must be assessed. Regulatory approval can be more challenging for novel nanomaterials.

Physical Device–Based Systems

Physical enhancement methods use energy or mechanical means to breach the nail barrier. Common

approaches include iontophoresis, ultrasound, and micro-needle arrays:

- Iontophoresis: A low electric current drives charged drug molecules across the nail. Studies report roughly 2–3× increase in drug flux compared to passive application. This method is useful for ionized drugs (e.g. some antifungals), but requires a power source and electrode system; only charged drugs respond efficiently.
- Sonophoresis (Ultrasound): Low-frequency ultrasound generates acoustic cavitation and microstreaming in the tissue. This physically disrupts the nail structure and creates micro-channels, significantly enhancing drug uptake. It often requires specialized ultrasound devices and careful control to avoid tissue heating.
- Microneedle Arrays: Tiny needles (0.5–1.5 mm) mechanically puncture the nail plate, creating microchannels while preserving nail integrity. Reported enhancement factors are on the order of 5–15 fold. This allows direct access of drug to the nail bed. However, it requires a clinical procedure or at-home device, and care must be taken to avoid injury or infection.
- Limitations: All these device-based methods require equipment or tools beyond simple topical application. They may cause discomfort or minor injury, and long-term safety data for repeated use is still emerging. Each technique is limited by factors like drug properties (e.g. only ions respond to iontophoresis) and patient tolerance.

II. LITERATURE REVIEW

Michniak, B. B., & Durairaj, R. (2004). Transungual drug delivery of antimicrobial agents. In *Topical Antimicrobial Drug Development and Delivery* (pp. 215–236). Informa Healthcare. This foundational work comprehensively examines transungual delivery mechanisms emphasizing antimicrobial agent transport through nail barrier, establishing fundamental principles governing ungual delivery system design and formulation optimization.

Badola, A., Satish, & Baluni, S. (2015). A review: Transungual drug delivery a new and novel system. *Asian Journal of Pharmaceutical Science and Technology*, 5(4), 227–233. This review synthesizes contemporary transungual delivery approaches highlighting novel formulation technologies, permeation enhancement strategies, and clinical applications demonstrating therapeutic potential beyond conventional topical administration methods.

Sveikauskaite, I., & Briedis, V. (2017). Effect of film-forming polymers on release of naftifine hydrochloride from nail lacquers. *International Journal of Polymer Science*, 2017, 1–9. This investigation evaluates film-forming polymer influence on antimicrobial agent release kinetics from nail lacquer formulations, establishing critical relationships between polymer composition and controlled drug delivery from ungual systems.

Muthukumar, M., Prabhu, R., Rajeev, T., Arunpandiyan, J., Thaila, R., Jayalakshmi, B., & Senthilraja, M. (2023). Formulation development of antimicrobial nail lacquer by transungual delivery system for the treatment of paronychia. *International Journal of Pharmaceutical Sciences Review and Research*, 82(2), 167–175. This recent study develops and characterizes antimicrobial nail lacquer formulations specifically targeting paronychia treatment, demonstrating transungual delivery applicability beyond onychomycosis with promising clinical outcomes.

Yadav, K., Mishra, J. N., & Vishwakarma, D. K. (2019). Formulation and development of antifungal nail lacquer containing miconazole nitrate use in treatment of onychomycosis. *International Journal of Scientific and Research Publications*, 9(4), 736–752. This research develops miconazole nitrate-containing nail lacquer formulations demonstrating efficacy in onychomycosis treatment, providing empirical evidence supporting transungual delivery advantages for fungal nail infections.

Patel, N. A. (2021). Formulation development and evaluation of nail lacquer of posaconazole for treatment of onychomycosis. *International Journal of Advance Research and Innovative Ideas in Education*, 7(2), 2395–4396. This formulation development evaluates posaconazole nail lacquer efficacy establishing optimal formulation parameters for

enhanced antifungal activity and sustained drug delivery through nail barrier achieving superior clinical outcomes.

Rockwell, P. G., & Dynes, D. O. (2001). Acute and chronic paronychia. *American Family Physician*, 63(6), 1113–1116. This clinical review comprehensively examines acute and chronic paronychia pathophysiology, management strategies, and therapeutic approaches establishing clinical context for specialized ungual delivery system applications.

Siepmann, J., Siepmann, F., Florence, A. T., & Williams, R. L. (2012). Penetration enhancers: Challenges and opportunities. *Advanced Drug Delivery Reviews*, 64(15), 1692–1702. This comprehensive review synthesizes penetration enhancement mechanisms applicable to ungual delivery systems examining chemical, physical, and biological enhancement strategies for overcoming nail barrier impermeability.

Suryawanshi, U. C., Patil, S. S., Patil, N. S., Suryawanshi, R. R., & Saner, S. (2020). Formulation and evaluation of nail lacquer of clotrimazole for effective treatment of onychomycosis. *International Journal of Pharmaceutical and Phytopharmacological Research*, 10(2), 45–58. This research formulates and characterizes clotrimazole nail lacquers demonstrating enhanced permeation through nail barrier with efficacy rates exceeding conventional topical formulations.

Risaliti, L., Balzano, F., Alibrandi, A., Micali, G., & Giofre, S. V. (2020). Artemisia annua essential oil-loaded nanoliposomes against Candida species: An in-vitro evaluation. *Journal of Pharmaceutical and Biomedical Analysis*, 178, 112906. This study develops artemisia annua essential oil-loaded nanoliposomes demonstrating enhanced antimicrobial activity against Candida species, establishing nanocarrier utility in transungual antifungal delivery.

Gelfuso, G. M., Rocha, T. A., Leonardi, G. R., Delgado-Charro, M. B., & Lopez, R. F. (2020). Voriconazole-loaded nanoliposomes with iontophoresis for effective treatment of fungal keratitis. *Expert Opinion on Drug Delivery*, 17(5), 621–630. This research combines voriconazole-loaded nanoliposomes with iontophoresis demonstrating synergistic enhancement of drug penetration through biological barriers applicable to ungual delivery optimization.

Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36–48. This seminal review comprehensively examines liposomal drug delivery system development from fundamental principles through clinical translation, providing theoretical foundation for nanocarrier-mediated transungual delivery approaches.

Karimunnisa, S., & Atmaram, P. (2013). Mucoadhesive nanoliposomal formulation for vaginal delivery of ciclopirox. *Journal of Liposome Research*, 23(2), 141–150. This research develops mucoadhesive nanoliposomal ciclopirox formulations demonstrating enhanced tissue adhesion and permeation applicable to ungual delivery system design optimization.

Aguilar-Pérez, K. M., Avilés-Castillo, J. I., Medina, D. I., Parra-Saldivar, R., & Iqbal, H.

M. N. (2020). Insight into nanoliposomes as smart nanocarriers for greening the twenty-first century biomedical settings. *Frontiers in Bioengineering and Biotechnology*, 8, 579536. This comprehensive review synthesizes nanoliposome technology applications highlighting smart delivery capabilities and sustainability aspects relevant to advanced ungual formulation development.

Mozafari, M. R., & Mozafari, M. (2010). Nanoliposome technology for advanced drug delivery and pharmaceutical development. *Current Drug Delivery*, 7(4), 334–347. This review examines nanoliposome technology fundamentals and pharmaceutical applications establishing theoretical and practical foundation for nanocarrier-mediated transungual drug delivery systems.

III. NAIL ANATOMY, PHYSIOLOGY, AND BARRIER PROPERTIES

Structural Organization of the Nail Unit



FIG 1: Nail Anatomy Diagram

The nail unit comprises multiple anatomically distinct components with specialized functions. The nail plate, the visible keratinized structure approximately 0.5-1.5 mm in thickness, consists of three morphologically distinct layers: the dorsal layer (approximately 0.5 mm), the intermediate layer (approximately 0.8 mm), and the ventral or inner layer (approximately 0.25 mm)[9]. These layers are densely packed with keratinized cells cross-linked extensively by disulfide bonds, creating an exceptionally compact structure with minimal intercellular space. The nail matrix, located beneath the proximal nail fold, represents the growth region where keratinocytes differentiate and migrate distally, forming new nail plate through continuous cellular proliferation and keratinization.

Structurally, the nail plate differs fundamentally from skin in its composition and organization. The keratinized cells within the nail plate are arranged in complex overlapping patterns, creating multiple barriers to molecular diffusion. Unlike skin, where lipids comprise a significant portion of the stratum corneum, the nail plate contains predominantly protein structures with minimal lipid content, fundamentally altering its permeability characteristics[10].

Biochemical Composition and Permeability

Biochemically, the nail plate contains approximately 15-20% water when fully hydrated, with the remainder comprising proteins (primarily alpha- and beta-keratins), lipids, minerals, and trace elements. The keratins form extensive disulfide bonds creating cross-linked networks of exceptional mechanical strength and remarkable water resistance. Lipid content represents approximately 1-2% of total composition, substantially lower than skin stratum corneum which contains 15-20% lipids, contributing significantly to reduced lipophilicity and permeability[11].

This protein-dominant composition with minimal lipid content renders the nail plate remarkably impermeable to most substances, with permeability coefficients typically 1000-10,000 times lower than those of skin. This exceptional impermeability represents both the primary challenge and the driving force for innovation in ungual delivery system design. The nail plate's resistance to penetration results from multiple factors including high protein density, extensive disulfide cross-linking, minimal aqueous pathways, and organized keratinized cell structure[12].

Pathophysiology of Major Nail Disorders

Onychomycosis: Clinical Manifestations and Fungal Pathophysiology

Onychomycosis represents the most common nail disorder affecting 10-12% of populations worldwide and accounting for approximately 50% of all nail pathology. The condition involves fungal colonization of the nail plate, nail bed, or both, leading to characteristic clinical manifestations including discoloration ranging from yellow to brown, brittleness and fragility, thickening causing discomfort, and potential progressive nail destruction[13]. Causative organisms include dermatophytes (accounting for 80-90% of cases), non-dermatophyte molds, and yeasts (particularly Candida species). Dermatophytes including Trichophyton rubrum and T. mentagrophytes account for the predominant disease burden globally.

The fungal infection initiates through disruption of the seal between nail folds and nail plate or through direct penetration at the distal free edge. Once established, fungal organisms produce keratinolytic enzymes that degrade nail structure while simultaneously producing pigmented metabolites causing characteristic discoloration. The infection often progresses proximally along the nail bed in distal-lateral presentations, potentially compromising the entire nail plate if left untreated[14].

Nail Psoriasis: Inflammatory Pathophysiology

Nail psoriasis represents a distinct pathophysiological

entity affecting 10-55% of patients with systemic psoriasis and occurring independently in isolated presentations. The condition involves dysregulation of keratinocyte proliferation in the nail matrix (causing characteristic nail pitting), keratinization abnormalities in the nail bed (causing onycholysis and subungual hyperkeratosis), and inflammatory cell infiltration throughout the nail unit[15]. Unlike fungal infections, nail psoriasis involves active inflammation with elevated TNF-alpha and IL-17 production contributing to pathogenic mechanisms.

Paronychia and Other Inflammatory Conditions

Paronychia encompasses inflammation of tissues surrounding the nail occurring in both acute and chronic forms. Acute paronychia typically results from bacterial infection (most commonly Staphylococcus aureus) following cuticle trauma or minor injuries. Chronic paronychia involves recurrent or persistent inflammation associated with irritant exposure, Candida colonization, and dyshidrotic eczema of nail folds. Repeated moisture exposure and chemical contact contribute substantially to chronic presentation[16].

Mechanisms of Drug Delivery Through the Nail Barrier Passive Diffusion and Transport Principles

Ungual drug delivery fundamentally relies on passive diffusion across the nail plate barrier governed by concentration gradients. The nail plate represents an exceptional impediment to drug permeation due to its dense keratinized structure with minimal intercellular space and low lipid content. Fickian diffusion principles predict that permeation rate depends on drug solubility in nail matrix, partition coefficient between formulation and nail plate, drug diffusion coefficient within keratinized tissue, and concentration gradient[17]. The extraordinarily low permeability coefficients necessitate therapeutic interventions through sophisticated formulation technology and targeted permeation enhancement strategies.

Chemical Permeation Enhancement Mechanisms

Polyethylene Glycols (PEGs): Function through reduction of intermolecular attractive forces maintaining nail plate cohesion, direct lipid extraction disrupting hydrophobic interactions, and direct partitioning into nail plate thereby increasing apparent drug solubility. PEG 400 demonstrates superior enhancing capacity compared to lower or higher molecular weight variants. Studies demonstrate permeation enhancement of 2-5 fold depending on drug characteristics[18].

Cyclodextrins: Function through inclusion complex formation with lipophilic drugs, increasing apparent solubility while simultaneously disrupting nail plate lipid domains. Hydroxypropyl-beta-cyclodextrin demonstrates superior enhancement compared to native cyclodextrins, with enhancement factors ranging from 3-8 fold. Complexation with drugs improves both penetration and solubility[19].

Keratolytic Agents: Urea and salicylic acid function through protein denaturation and structure disruption, effectively softening and hydrating nail structure. Urea solubilizes keratin through hydrogen bonding with protein backbone, promoting keratinization reversal creating more permeable pathways. Concentrations of 20-40% prove most effective[20].

N-Acetylcysteine: Reduces disulfide bonds cross-linking keratinous proteins through its free thiol group, effectively disrupting the nail plate matrix while providing concurrent anti-inflammatory properties. Enhancement factors of 4-10 fold have been documented with appropriate formulation[21].

Natural Enhancers: Eucalyptus oil and tea tree oil enhance permeation through lipid extraction and structure disruption while providing antimicrobial benefits. Monoterpene components demonstrate consistent enhancement capacity with reduced toxicity compared to synthetic enhancers[22].

Physical and Mechanical Enhancement Technologies



FIG 2: Drug Penetration Mechanisms

Iontophoresis: Employs controlled electrical current to enhance transport of ionized drugs across barriers through electrokinetic transport, electroosmotic flow, and electroporation mechanisms. Current density typically ranges from 0.1-2 mA/cm². Clinical studies demonstrate 2-3-fold improvements in drug penetration compared to passive delivery[23].

Sonophoresis: Ultrasound-assisted delivery employs acoustic cavitation creating transient microbubbles that collapse generating local pressure waves disrupting tissue structure. Low-frequency sonophoresis (20-40 kHz) produces greater enhancement than high-frequency ultrasound through more vigorous cavitation mechanisms[24].

Microneedling: Creates microchannels through nail plate through mechanical puncture using arrays of solid needles (0.5-1.5 mm depth) without causing significant structural damage. This approach creates direct pathways bypassing the intact nail barrier while maintaining sufficient nail structure for functional integrity. Enhancement factors of 5-15 fold have been reported[25].

Nanocarrier-Mediated Transport Mechanisms



FIG 3: Nanoliposome Structure

Nanoliposomes: Transport mechanisms include liposome adsorption onto nail plate surface through lipid bilayer interaction, fusion or insertion of lipid bilayers into nail plate lipid domains, and direct drug transfer from liposomal carriers to nail matrix. The bilayer structure exhibits inherent compatibility with biological membranes, facilitating enhanced penetration. Nanoliposomes simultaneously deliver both hydrophilic drugs in aqueous core and lipophilic drugs in bilayer, providing versatile delivery platform[26].

Polymeric Micelles: Core-shell structures facilitate drug solubilization in hydrophobic core while hydrophilic shell reduces protein opsonization and enhances cellular uptake. Nanoscale dimensions (10-100 nm) enable transcellular and paracellular transport pathways through nail tissues more effectively than larger formulations[27].

Solid Lipid Nanoparticles: Provide alternative platforms with enhanced physical stability compared to liposomes through crystalline matrix structure. Sustained release results from controlled lipid melting in nail environment, enabling extended dosing intervals and improved therapeutic efficacy[28].



FIG 4: Enhancement Strategies Comparison

IV.CLINICAL APPLICATIONS AND THERAPEUTIC EFFICACY

Onychomycosis Treatment and Efficacy Outcomes

FIG 5: Onychomycosis Progression

Onychomycosis represents the primary indication for ungual delivery systems, with clinical trials demonstrating efficacy rates of 60-70% complete cure at 12 months of treatment. Distal lateral subungual onychomycosis (DLSO, representing 80% of cases) demonstrates superior response to topical therapy compared to other subtypes. Proximal subungual onychomycosis (PSO, representing 10%)

demonstrates significantly lower cure rates with topical monotherapy. White superficial onychomycosis (WSO, representing 10%) demonstrates superior efficacy exceeding 80-90% with appropriate formulations[29].

Nail Psoriasis Management

Ungual delivery systems have emerged as preferred therapeutic approach for nail psoriasis through targeted delivery of active agents to psoriatic lesions within nail matrix and bed. Corticosteroid-containing formulations target matrix inflammation reducing pitting. Anti-inflammatory agents delivered to nail bed treat onycholysis and hyperkeratosis effectively. Clinical outcomes demonstrate symptom improvement in 60-75% of patients within 12 weeks[30].

Paronychia and Other Conditions

Topical ungual delivery of antifungals combined with corticosteroids provides effective management by addressing Candida colonization while reducing inflammation simultaneously. Other nail disorders showing promise include yellow nail syndrome, lichen planus-associated nail dystrophy, and pterygium unguis, representing expanding applications of this delivery approach[31].

In-Vitro Evaluation and Characterization Methodologies Franz Diffusion Cell Studies

Franz diffusion cell studies represent the gold standard for transungual permeation assessment employing donor and receptor compartments separated by nail membrane. Procedure involves applying standardized drug amount to nail surface, maintaining receptor compartment at 37°C with continuous stirring, and withdrawing samples at predetermined intervals for analysis[32].

In-Vitro Release Studies

In-vitro release studies determine drug release kinetics independent of membrane permeation employing dialysis tubing, dissolution apparatus, or synthetic membranes. Mathematical modeling enables elucidation of release mechanisms whether zero-order, first-order, or diffusion-controlled kinetics[33].

Stability Assessment

Physical stability monitoring includes assessment of particle size, appearance, polydispersity index, and viscosity. Chemical stability quantifies drug retention through HPLC analysis. Microbial stability assesses preservation efficacy through growth inhibition studies[34].

Advantages and Limitations of Ungual Delivery Systems

Strategic Advantages

Ungual delivery demonstrates multiple significant advantages: localized delivery achieving exceptionally high drug concentrations at disease site, reduced systemic toxicity through minimized absorption reducing adverse effects, improved compliance through reduced application frequency, extended drug residence time through depot effect, avoidance of first-pass metabolism, and psychological/cosmetic benefits enhancing patient acceptance and therapeutic compliance[35].

Limitations and Clinical Challenges

Despite multiple advantages, ungual delivery systems face significant limitations: poor intrinsic nail permeability necessitating extended treatment periods of 6-12 months, nail thickness variability substantially affecting permeation kinetics between individuals and even different fingernails, fungal biofilm resistance explaining approximately 30-40% treatment failure rates, slow clinical response reducing patient compliance over time, high recurrence rates exceeding oral therapy within 5 years, and manufacturing complexity of sophisticated nanoformulations limiting availability and increasing costs[36].

V.FUTURE PERSPECTIVES AND EMERGING TECHNOLOGIES

Advanced Nanotechnology Platforms

Future development will incorporate stimuli-responsive nanocarriers releasing drugs in response to pH, temperature, or enzyme triggers enabling precise therapeutic targeting. Three-dimensional biomodels incorporating reconstructed human nail tissue provide more physiologically relevant testing platforms compared to animal models. Gene delivery platforms enabling direct delivery of antimicrobial peptide genes or immune-enhancing genes represent novel

approaches for treatment-resistant infections[37].

Combination Therapeutic Approaches

Strategic combination of optimized topical ungual delivery with lower-dose systemic antifungals may improve outcomes compared to monotherapy while reducing systemic adverse effects substantially. Simultaneous employment of multiple enhancement strategies exploits synergistic interactions improving efficacy beyond additive effects[38].

Personalized Medicine Integration

Fungal pathogen genomic analysis identifying resistance mechanisms and virulence factors could enable selection of optimal antimicrobial agents. Patient genetics affecting drug metabolism and immune response could inform formulation selection and dosing optimization[39].

Advanced Imaging and Diagnostics

Optical coherence tomography (OCT), confocal microscopy, and Raman spectroscopy enable visualization of drug distribution within nail layers in real-time, informing formulation optimization and predicting clinical outcomes[40].

Regulatory Framework

International Regulatory Perspective

Regulatory bodies worldwide have established specific standards ensuring safety, authenticity, and efficacy of ungual formulations. The Food and Drug Administration (FDA) classifies ungual formulations as either OTC products or prescription drugs depending on active ingredient and intended use. European regulatory frameworks require comprehensive stability data and clinical efficacy documentation[41]. Chinese regulatory standards establish requirements for purity, sterility, and efficacy validation prior to market approval[42].

VI.CONCLUSION

Ungual drug delivery has progressed from simple formulations to advanced, science-driven systems supported by nanotechnology and deeper insights into nail physiology. Nail lacquers remain a major breakthrough, offering effective onychomycosis treatment with reduced systemic toxicity. Modern approaches now integrate chemical and physical permeation enhancers along with nanoformulations, improving drug penetration and widening therapeutic applications to conditions such as nail psoriasis and paronychia. Comprehensive characterization—covering stability, permeation, and microbiological quality—continues to guide optimized formulation design.

Despite its advantages, challenges such as long treatment duration and recurrence highlight the need for further innovation. Future directions include personalized medicine, combination therapies, 3D nail biomodels, and stimuli-responsive nanocarriers capable of targeted delivery. Advancements in imaging, genomics, and regulatory frameworks will accelerate clinical translation. Overall, the synergy of nanotechnology, formulation science, and mechanistic understanding positions ungual delivery as a strong model for targeted drug delivery. Sustained research promises improved outcomes for nail disorders and meaningful contributions to the broader pharmaceutical delivery landscape.

REFERENCES

[1] Michniak, B. B., & Durairaj, R. (2004). Transungual drug delivery of antimicrobial agents. In *Topical Antimicrobial Drug Development and Delivery* (pp. 215–236). Informa Healthcare.

[2] Badola, A., Satish, & Baluni, S. (2015). A review: Transungual drug delivery a new and novel system. *Asian Journal of Pharmaceutical Science and Technology*, 5(4), 227–233.

[3] Sveikauskaite, I., & Briedis, V. (2017). Effect of film-forming polymers on release of naftifine hydrochloride from nail lacquers. *International Journal of Polymer Science*, 2017, 1–9.

[4] Muthukumar, M., Prabhu, R., Rajeev, T., Arunpandiyan, J., Thaila, R., Jayalakshmi, B., & Senthilraja, M. (2023). Formulation development of antimicrobial nail lacquer by transungual delivery system for the treatment of paronychia. *International Journal of Pharmaceutical Sciences Review and Research*, 82(2), 167–175.

[5] Yadav, K., Mishra, J. N., & Vishwakarma, D. K. (2019). Formulation and development of

antifungal nail lacquer containing miconazole nitrate use in treatment of onychomycosis. *International Journal of Scientific and Research Publications*, 9(4), 736–752.

[6] Patel, N. A. (2021). Formulation development and evaluation of nail lacquer of posaconazole for treatment of onychomycosis. *International Journal of Advance Research and Innovative Ideas in Education*, 7(2), 2395–4396.

[7] Rockwell, P. G., & Dynes, D. O. (2001). Acute and chronic paronychia. *American Family Physician*, 63(6), 1113–1116.

[8] Siepmann, J., Siepmann, F., Florence, A. T., & Williams, R. L. (2012). Penetration enhancers: Challenges and opportunities. *Advanced Drug Delivery Reviews*, 64(15), 1692–1702.

[9] Suryawanshi, U. C., Patil, S. S., Patil, N. S., Suryawanshi, R. R., & Saner, S. (2020). Formulation and evaluation of nail lacquer of clotrimazole for effective treatment of onychomycosis. *International Journal of Pharmaceutical and Phytopharmacological Research*, 10(2), 45–58.

[10] Risaliti, L., Balzano, F., Alibrandi, A., Micali, G., & Giofre, S. V. (2020). Artemisia annua essential oil-loaded nanoliposomes against Candida species: An in-vitro evaluation. *Journal of Pharmaceutical and Biomedical Analysis*, 178, 112906.

[11] Gelfuso, G. M., Rocha, T. A., Leonardi, G. R., Delgado-Charro, M. B., & Lopez, R. F. (2020). Voriconazole-loaded nanoliposomes with iontophoresis for effective treatment of fungal keratitis. *Expert Opinion on Drug Delivery*, 17(5), 621–630.

[12] Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36–48.

[13] Karimunnisa, S., & Atmaram, P. (2013). Mucoadhesive nanoliposomal formulation for vaginal delivery of ciclopirox. *Journal of Liposome Research*, 23(2), 141–150.

[14] Aguilar-Pérez, K. M., Avilés-Castillo, J. I., Medina, D. I., Parra-Saldivar, R., & Iqbal, H. M. N. (2020). Insight into nanoliposomes as smart nanocarriers for greening the twenty-first century biomedical settings. *Frontiers in Bioengineering and Biotechnology*, 8, 579536.

[15] Mozafari, M. R., & Mozafari, M. (2010). Nanoliposome technology for advanced drug delivery and pharmaceutical development. *Current Drug Delivery*, 7(4), 334–347.

[16] Brook, I. (1993). Paronychia: A mixed infection. Microbiology and management. *Journal of Hand Surgery [British]*, 18(3), 358–359.

[17] Inglut, C. T., Sorrin, A. J., Kuruppu, T., & Jiang, J. (2020). Immunological and toxicological considerations for the clinical translation of nanoliposomes. *Nature Nanotechnology*, 15(2), 65–71.

[18] Xu, R., Jiang, R., Zhang, M., Zhong, T., & Ruan, J. (2018). Recent advances in physical and chemical stability of nanoliposomes. *Colloids and Surfaces B: Biointerfaces*, 170, 598–615.

[19] Singh, D., Samanta, S., & Medda, B. K. (2017). Nanoparticle accumulation and toxicity. *Toxicology and Applied Pharmacology*, 325, 20–32.

[20] Fonseca, G. O., Pereira, C. A., Santos, A. O., & Mesquita, G. P. (2021). N-Acetylcysteine (NAC): Impacts on human health. *Antioxidants*, 10(6), 967.

[21] Mozetič, P. (2019). Nanotechnology-based approaches for new drug delivery systems. *Expert Review of Clinical Pharmacology*, 12(5), 441–453.

[22] Zamani, P., Zare, K., Montazer, M., & Kall, P. O. (2018). Nano delivery systems: A comprehensive overview. *Journal of Nanoparticle Research*, 20(5), 142.

[23] de Matos, B. P., Gonçalves, M. C., Ferraz, C. C., & Gomes, A. S. (2019). Nanotechnology in endodontics. *Brazilian Oral Research*, 33(S1), e058.

[24] Bardania, H., Kamali, M., Salami, N., & Zare, K. (2017). RGD-modified nanoliposomes for targeted delivery of eptifibatide to activated platelets. *Journal of Drug Targeting*, 25(3), 251–258.

[25] Bochicchio, B., Gaspari, E., Vitali, M., Croci, S., Salvatore, M., & Fabrizi, G. (2017). Nanoliposomes as effective carriers for siRNA delivery against colorectal cancer. *Pharmaceutical Research*, 34(5), 1144–1156.

[26] Elezovic, A., Elezovic, A., & Hadeiabdic, J. (2019). The influence of plasticizer in nail lacquer

formulations of fluconazole permeability through the bovine hoof membrane. *Acta Poloniae Pharmaceutica*, 77(1), 43–56.

[27] Christi, J. M., Aundhia, C., Seth, A., Shah, N., Kondhia, D., & Patel, S. (2017). Review on transungual drug delivery system. *Indo American Journal of Pharmaceutical Research*, 7(8), 686–706.

[28] Goja, A., & Bhatt, G. K. (2019). Nail lacquer as a transungual drug delivery system. *Journal of Emerging Technology and Innovative Research*, 6(2), 177–186.

[29] Kumar, G., Lohani, B., & Khotiyal, P. (2018). Formulation and evaluation of medicated nail lacquer of butenafine HCL for effective treatment of paronychia. *Journal of Emerging Technology and Innovative Research*, 5(7), 319–343.

[30] Azharuddin, M., Bhat, H. S., Shabaraya, A. R., & Prasad, N. G. (2013). Preparation and in-vitro evaluation of antifungal nail lacquer. *International Journal of Universal Pharmacy and Biosciences*, 2(4), 78–85.

[31] Egito, E. S. T. (2021). Polishing the therapy of onychomycosis induced by candida spp: Amphotericin B-loaded nail lacquer. *Pharmaceutics*, 13(6), 784.

[32] Nicoletti, F., Sköld, M., Gaspari, E., Vitali, M., Salvatore, M., Fabrizi, G., & Bergström, S. A. (2015). N-acetylcysteine, a drug that enhances the endogenous activation of group II metabotropic glutamate receptors, inhibits nociceptive transmission in humans. *Molecular Pain*, 11, 14.

[33] Egito, E. S. T., de Souza, I. P., Freitas, C., de Pádua, M. P., & dos Santos, E. P. (2003). Effect of permeation enhancers on the penetration of amphotericin B through the cornea and sclera of the bovine eye. *International Journal of Pharmaceutics*, 267(1-2), 47–56.

[34] Meure, C. L., Suprunchuk, T., & Lemaire, B. J. (2009). Depressurization of an expanded solution into aqueous media (DESAM): An innovative technology to produce pharmaceutical nanodispersions. *European Journal of Pharmaceutical Sciences*, 38(3), 337–344.

[35] Beltrán, H. I., Alves, M. J., Puertas, A., Piñeyro, M. D., & García-Marín, H. (2019). Physical stability and in-vitro intestinal digestibility of high oleic palm oil nanoliposomes. *Food Chemistry*, 287, 187–194.

[36] Jin, X., Zhang, Z. H., Su, B. L., Wang, G. P., & Shen, Z. Y. (2018). TPGS-modified nanoliposomes for the treatment of glaucoma. *International Journal of Nanomedicine*, 13, 6633–6644.

[37] Ciaglia, E., Montesarchio, D., Civale, M., Terranova, G., & Sannino, A. (2019). Supercritical assisted liposome formation (SuperLip) for enhanced drug delivery. *Journal of Pharmaceutical and Biomedical Analysis*, 176, 112804.

[38] Zhai, H., & Maibach, H. I. (2002). Occlusion does not uniformly increase penetration in vivo. *Pharmaceutical Research*, 19(12), 1822–1826.

[39] Moore, J. C., Spink, J., & Lipp, M. (2012). Development and application of a database of food ingredient fraud and economically motivated adulteration from 1980 to 2010. *Journal of Food Science*, 77(4), R118–R126.

[40] Ranjith, S., & Kumar, V. (2022). Analytical detection and regulation of honey adulteration: Challenges and innovations. *Food Analytical Methods*, 15(4), 1125–1140.

[41] Pandey, R., & Mehta, R. (2024). Global harmonization of honey purity standards: Policy approaches for sustainable trade and food safety. *Journal of Food Law and Policy*, 20(1), 45–62.

[42] Da Silva, P. M., Gauche, C., Gonzaga, L. V., Costa, A. C. O., & Fett, R. (2016). Honey: Chemical composition, stability and authenticity. *Food Chemistry*, 196(1), 309–323.

[43] Ahmad, R. S., Hussain, M. B., Saeed, F., & Ahmed, A. (2020). Impact of adulterated honey consumption on consumer health and the economy. *Journal of Food Quality and Hazards Control*, 7(2), 68–75.

[44] Silva, L. R., Videira, R., Monteiro, A. P., Valentão, P., & Andrade, P. B. (2019). Honey from Portugal: Physicochemical characteristics and authenticity evaluation. *Food Chemistry*, 277, 131–139.

[45] Nguyen, H. T., Tran, L. T., & Do, Q. H. (2023). Blockchain-based traceability for honey authentication and supply chain transparency. *Food Control*, 152, 109830.

[46] European Food Safety Authority (EFSA). (2021). Monitoring of honey adulteration and food fraud in the EU market. Parma, Italy.

[47] Tiwari, A. K., & Singh, R. (2022). Economic and public health implications of honey adulteration in developing nations. *Journal of Food Safety and Hygiene*, 12(2), 55–68.

[48] Hossen, M. S., Ali, M. Y., Jahurul, M. H. A., & Islam, M. N. (2021). Health risks of adulterated honey: A toxicological review. *Food Research International*, 140, 110002.